In lung cancer, for example, YAP1 activation confers resistance to therapies targeted against common lung cancer oncogenes, such as anaplastic lymphoma kinase (ALK), BRAF or mutated epidermal growth factor receptor (EGFR) tyrosine kinase. This evidence concerns the gene EGFR and lung carcinoma.